Additionally, we did not observe differences in tumor mutational burden (TMB) (9.46 ± 4.46 for CRS1; 9.14 ± 2.41 for CRS2; 9.31 ± 2.33 for CRS3) or in the type of base-pair substitution and indels between patient groups (Fig. 1a). This evidence concerns the gene MSX2 and neoplasm.